Considering the possible overlapping pathophysiological mechanisms, this would lead to speculate about the possible use of MEK inhibitors in NF1 patients with severe skeletal abnormalities, which demonstrated effective in patients with NF1-associated tumors and plexiform neurofibromas. This evidence concerns the gene MAP2K7 and neurofibromatosis type 1.